Second in a three part series that explores the diverse organizational and strategic decisions, the company as a result of the global AIDS epidemic now facing. Heineken is considering one of the first companies to AIDS drugs (antiretroviral therapy) to provide employees and their families. Must consider Hans Wesseling, the corporate HR manager and his colleagues in the medical department of the organizational, financial and social impact of this decision and a recommendation to … Read more »

Second in a three part series that explores the diverse organizational and strategic decisions, the company as a result of the global AIDS epidemic now facing. Heineken is considering one of the first companies to AIDS drugs (antiretroviral therapy) to provide employees and their families. Must consider Hans Wesseling, the corporate HR manager and his colleagues in the medical department of the organizational, financial and social impact of this decision and recommendation to the Board. Shows how Heineken is responding to the epidemic, and it is., As part of Corporate Social Responsibility
«Hide

from
Diana Barrett,
Daniella Ballou
Source: Harvard Business School
7 pages.
Publication Date: Jan 27, 2003. Prod #: 303064-PDF-ENG
Heineken NV: Workplace HIV / AIDS programs in Africa (B) HBR case solution